Here we show that in diabetics without baseline CKD, higher baseline Lp(a) concentrations, including above the clinical used atherogenic cutpoint of 30 mg/dL, are strongly associated with decline in eGFR. The gene discussed is LPA; the disease is chronic kidney disease.